27 May 2024
27 May 2024
Dr Robert Danby from UK stem cell charity Anthony Nolan said that changes have been made but more needs to be done.
Keeping high-qualified, experienced clinical trial staff on board plays a crucial role in bringing new drugs to market. Dana Durkan of KPS Life discusses how to avoid fraudulent staff, navigate work from home dynamics, and keep hold of your most valued employees.
Experts at the OCT East Coast 2024 conference discussed the challenges and solutions for diverse recruitment, particularly as it pertains to rare disease.
Experts at OCT East Coast discuss the integral roles of patients and caregivers throughout a clinical trial’s lifecycle.
A total of 24 ALS patients were enrolled across seven study sites in India.
TerXT will be investigated in two Phase I trials before Terran will apply for approval after KarXT’s five-year exclusivity period.
Abdera intends to launch the Phase I clinical trial in the second half of this year.
The company licensed the ubiquitin-specific protease 1 (USP1) inhibiting cancer therapy from Medivir in 2020.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
GlobalData's latest report is the 14th edition offering an analysis of the CMO industry, using the FDA’s NDA approvals as the primary indicator of performance. The report is critical for benchmarking the performance of the CMO industry and the relative performance of major CMOs. This year’s edition includes a discussion of how inflation and increasing global conflict has impacted pharma manufacturers.
GlobalData's latest report is the 14th edition offering an analysis of the CMO industry, using the FDA’s NDA approvals as the primary indicator of performance. The report is critical for benchmarking the performance of the CMO industry and the relative performance of major CMOs. This year’s edition includes a discussion of how inflation and increasing global conflict has impacted pharma manufacturers.
GlobalData's latest report is the 14th edition offering an analysis of the CMO industry, using the FDA’s NDA approvals as the primary indicator of performance. The report is critical for benchmarking the performance of the CMO industry and the relative performance of major CMOs. This year’s edition includes a discussion of how inflation and increasing global conflict has impacted pharma manufacturers.
Give your business an edge with our leading industry insights.
